F-term Moduli Stabilization and Uplifting

We study K\"ahler moduli stabilization in IIB superstring theory. We propose a new moduli stabilization mechanism by the supersymmetry-braking chiral superfield which is coupled to K\"ahler moduli in K\"ahler potential. We also study uplifting of the Large Volume Scenario (LVS) by it. In both cases, the form of superpotential is crucial for moduli stabilization. We confirm that our uplifting mechanism does not destabilize the vacuum of the LVS drastically.Comment: 22 pages, 2 figure

教師のエンパワーメントを促進する要因についての研究

　本研究では，教師が学校の諸業務に対して意欲を向上したり，効力感を感得したりして，前向きで充実した教師生活を送れるようにするための源泉となるエンパワーメントの促進要因を明らかにすることを目的とする。そのために，エンパワーメントの定義を再確認しつつ，先行研究の成果をもとに，小学校教員にアンケート調査を行った結果，27の要因について見出すことができた

Pyrene-cored blue-light emitting [4]helicenes: synthesis, crystal structures, and photophysical properties

The synthesis, crystal structures and photophysical properties of two types of pyrene-cored blue-light emitting [4]helicenes are reported, in which two naphthalene rings of condensed pyrenes were constructed resulting in helical architectures. The photophysical properties and electrochemical characteristics of these pyrene-cored [4]helicenes were fully investigated in both solutions and films, along with that of the pre-cyclization Q4 products, 4,9- and 4,10-(phenylethenyl)pyrenes

Extended [pi]-conjugated pyrene derivatives: structural, photophysical and electrochemical properties

This article presents a set of extended [pi]-conjugated pyrene derivatives, namely 1,3-di(arylethynyl)-7-tert-butylpyrenes, which were synthesized by a Pd-catalyzed Sonogashira coupling reaction of 1,3-dibromo-7-tert-butylpyrenes with the corresponding arylethynyl group in good yields. Despite the presence of the tert-butyl group located at the 7-position of pyrene, X-ray crystallographic analyses show that the planarity of the Y-shaped molecules still exhibits strong face-to-face [pi]-[pi] stacking in the solid state; all of the compounds exhibit blue or green emission with high quantum yields (QYs) in dichloromethane. DFT calculations and electrochemistry revealed that this category of compound possesses hole-transporting characteristics. In addition, with strong electron-donating (-N(CH3)2) or electron-withdrawing (-CHO) groups in 2 d or 2 f, these molecules displayed efficient intramolecular charge-transfer (ICT) emissions with solvatochromic shifts from blue to yellow (green) on increasing the solvent polarity. Furthermore, the compounds 2 d and 2 f possess strong CT characteristics

20１１ネン カラ ２０１３ネン ノ ヤマガタケン ニ オケル ミッツ ノ コトナル イデンシガタ ノ ハイエン マイコプラズマ ノ チイキテキ ヒロガリ ト マクロライド タイセイ カブ シュツゲン ノ タイミング ニ カンスル ケントウ

Background: We previously revealed that several multiple-locus variable-number tandem-repeat analyses（MLVA）and P1 types of Mycoplasma pneumoniae（M. pneumoniae）cocirculated between 2011 and 2013 in Yamagata, Japan. However, the regional spread of M. pneumoniae infection by genotype is not reported yet. It remains unclear whether there is a difference in the spread of macrolide-resistant M. pneumoniae among genotypes. Methods: Genotypes were labeled according to 4-locus（Mpn 13, 14, 15, and 16）MLVA and P1 types. A total of 208 strains belonging to three major genotypes, i.e., type 4-5-7-2, 1; 4-5-7-3, 1; and 3-5-6-2, 2c, were analyzed by combining with the information of macrolide resistance-associated mutation and the patients’ information including residence. Results and Discussion: The three genotypes were widely distributed over more than four cities and towns in Yamagata Prefecture, cocirculating between late 2011 and early 2013, and there was little difference in the duration of their epidemics. Timing of macrolide-resistant strain appearance during the epidemic period differed between type 4-5-7-2, 1 and type 4-5-7-3, 1, and it did not appear throughout type 3-5-6-2, 2c epidemic. These genotypic differences can account for the variation in the prevalence of macrolide resistance-associated mutations in each of the studied areas

Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)

Objectives: To evaluate the efficacy and safety, we conducted a randomized phase II study of pemetrexed (Pem) versus Pem + bevacizumab (Bev) for elderly patients with non-squamous non-small cell lung cancer (NSqNSCLC). Patients and methods: The eligibility criteria were as follows: NSqNSCLC, no prior therapy,stage IIIB/IV disease or postoperative recurrence, age: ?75 years, performance status (PS): 0?1, and adequate bone marrow function. The patients were randomly assigned (1:1 ratio)to receive Pem or Pem + Bev. The primary endpoint was progression-free survival (PFS).The secondary endpoints were the response rate, OS, toxicities, and cost-effectiveness. Results: Forty-one patients were enrolled and 40 (20 from each group) were assessable. Their characteristics were as follows: male/female = 23/17; median age (range) = 78 (75?83); stage IIIB/IV/postoperative recurrence = 1/30/9; PS 0/1 = 11/29. All cases involved adenocarcinoma.There was no significant intergroup difference in PFS and the median PFS (95% confidence interval) values of the Pem and Pem + Bev groups were 5.4 (3.0?7.4) and 5.5 (3.6?9.9) months, respectively (p = 0.66). The response rate was significantly higher in the Pem + Bev group(15% vs. 55%, p = 0.0146), and there was no significant difference in OS (median: 16.0 vs. 16.4 months, p = 0.58). Grade 3 and 4 leukopenia, neutropenia,and thrombocytopenia were seen in 10 and 30, 20 and 55, and 5 and 5 cases, respectively. Drug costs were higher in the Pem + Bev group (median: 1,522,008 vs. 3,368,428 JPY, p = 0.01). No treatment-related deaths occurred. Conclusions: Adding Bev to Pem did not result in improved survival in the elderly NSqNSCLC patients. Compared with Pem + Bev, Pem monotherapy had similar effects on survival, a more favorable toxicity profile, and was more cost-effective in elderly NSqNSCLC patients. Pem monotherapy might be one of the optional regimen for NSqNSCLC patients aged ?75 years

Clonality and Micro-Diversity of a Nationwide Spreading Genotype of Mycobacterium tuberculosis in Japan

Mycobacterium tuberculosis transmission routes can be estimated from genotypic analysis of clinical isolates from patients. In Japan, still a middle-incidence country of TB, a unique genotype strain designated as \u27M-strain\u27 has been isolated nationwide recently. To ascertain the history of the wide spread of the strain, 10 clinical isolates from different areas were subjected to genome-wide analysis based on deep sequencers. Results show that all isolates possessed common mutations to those of referential strains. The greatest number of accumulated single nucleotide variants (SNVs) from the oldest coalescence was 13 nucleotides, indicating high clonality of these isolates. When an SNV common to the isolates was used as a surrogate marker of the clone, authentic clonal isolates with variation in a reliable subset of variable number of tandem repeat (VNTR) genotyping method can be selected successfully from clinical isolates populations of M. tuberculosis. When the authentic clones can also be assigned to sub-clonal groups by SNVs derived from the genomic comparison, they are classifiable into three sub-clonal groups with a bias of geographical origins. Feedback from genomic analysis of clinical isolates of M. tuberculosis to genotypicmarkers will be an efficient strategy for the big data in various settings for public health actions against TB

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation